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The ability to bind extracellular matrix proteins is a critical virulence determinant for skin pathogens. Hae-
mophilus ducreyi, the etiological agent of the genital ulcer disease chancroid, binds extracellular matrix components,
including fibronectin (FN). We investigated H. ducreyi FN binding and report several important findings about this
interaction. First, FN binding by H. ducreyi was greatly increased in bacteria grown on heme and almost completely
inhibited by hemoglobin. Second, wild-type strain 35000HP bound significantly more FN than did a dsrA mutant in
two different FN binding assays. Third, the expression of dsrA in the dsrA mutant restored FN binding and conferred
the ability to bind FN to a non-FN-binding Haemophilus influenzae strain. Fourth, an anti-DsrA monoclonal
antibody partially blocked FN binding by H. ducreyi. The hemoglobin receptor, the collagen-binding protein, the H.
ducreyi lectin, the fine-tangle pili, and the outer membrane protein OmpA2 were not involved in H. ducreyi FN
binding, since single mutants bound FN as well as the parent strain did. However, the major outer membrane
protein may have a minor role in FN binding by H. ducreyi, since a double dsrA momp mutant bound less FN than
did the single dsrA mutant. Finally, despite major sequence differences, DsrA proteins from both class I and class
II H. ducreyi strains mediated FN and vitronectin binding. We concluded that DsrA is the major factor involved in
FN binding by both classes of H. ducreyi strains.
Haemophilus ducreyi is the cause of the sexually transmitted
ulcer disease chancroid (3, 32, 33, 39, 46). H. ducreyi is thought to
initiate infection by entering the skin through small abrasions
acquired during sexual intercourse (3, 33, 41). Thus, attachment
of H. ducreyi to extracellular matrix (ECM) proteins of the skin
may be an important initial step in the infection process, as shown
for other bacterial skin infections (8, 15, 37).
Little is known about the mechanisms employed by H.
ducreyi in the first critical steps of attaching to host skin. In
vitro, H. ducreyi binds to fibrinogen, fibronectin (FN), type I
and III collagen, gelatin, and laminin, but not elastin (2, 10).
FN may have a role in the interaction of H. ducreyi with
foreskin fibroblasts (4). During the later pustule stages of hu-
man experimental chancroid infection, H. ducreyi localizes with
inflammatory infiltrates present in pustules and colocalizes
with collagen and fibrin (9, 11). In naturally acquired chan-
croid, where patients are seen mostly at the last ulcerative
stage, H. ducreyi colocalizes with neutrophils and fibrin (12).
These data suggest that ECM binding by H. ducreyi may con-
tribute to chancroid pathogenesis.
Bacterial Oca (oligomeric coiled adhesion) proteins (25),
also referred to as trimeric autotransporters (17), comprise a
multifunctional family with demonstrated roles in binding to
ECM proteins, binding to various eukaryotic cells, mediating
invasion of cells, and resistance to killing by serum comple-
ment (21). Oca proteins are expressed on the bacterial surface
of the cell as homotrimers exhibiting a lollipop shape, with
head, neck, and stalk structures (21, 25). Different Oca family
members share similarity in the C-terminal domain, the region
that is believed to traverse and anchor the protein in the
bacterial outer membrane (25). However, Oca N-terminal do-
mains vary widely, even among family members expressed by
closely related species or within a species (25).
H. ducreyi expresses two Oca proteins, namely, DsrA (ducreyi
serum resistance A) and NcaA (necessary for collagen adhesion
A). Both were identified by their C-terminal similarity to the
prototypical Oca family protein YadA. DsrA was first described
as critical for high-level resistance to killing by normal human
serum (20) and was later shown to be an adhesin for HaCat
keratinocytes and to bind to vitronectin (VN) (16). DsrA is also
essential for H. ducreyi infection in the human challenge model of
chancroid (13). NcaA mediates type I collagen binding by H.
ducreyi and is also important for virulence of H. ducreyi in both the
porcine and human models of chancroid (22).
Recently, we identified two classes of H. ducreyi strains,
classes I and II (47), based on the presence of variant forms of
several outer membrane components, including DsrA, NcaA,
DltA (ducreyi lectin A), and lipooligosaccharide (LOS). The
DsrA proteins from the two classes of H. ducreyi strains have
almost identical C-terminal domains, sharing 88.5% identity in
the last 86 amino acids. However, these proteins have diver-
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gent N-terminal domains, sharing little amino acid sequence
similarity (47).
FNs are high-molecular-weight disulfide-linked glycoprotein
dimers found in both soluble and insoluble forms in human
blood and skin. The modular structure of FN promotes its
involvement in cell adhesion by binding to host cell integrins
and a plethora of other molecules present in the ECM and in
the blood (27, 34). Bacteria express MSCRAMMs (microbial
surface components recognizing adhesive matrix molecules),
adhesins that bind ECM proteins of the host, such as FN (29).
FN binding by MSCRAMMS has been studied widely in the
gram-positive genera Staphylococcus and Streptococcus (38),
and recent reports document the presence of such adhesins in
a broad variety of diverse genera, including gram-negative bac-
teria and mycobacterial species (29). FN binding by bacteria
occurs via different bacterial components (38) and is redun-
dant in many microorganisms, which may indicate the impor-
tance of this function in bacterial pathogenesis.
Given the importance of FN binding in other bacterial sys-
tems, the aim of this study was to investigate the role of DsrA
in FN binding by H. ducreyi.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Bacterial strains and plasmids used
in this study are shown in Tables 1 and 2, respectively. H. ducreyi strains were
routinely maintained by minimal subculture (no more than five passages) on
heme agar containing 50 g/l of hemin and 1 GGC (0.1% glucose, 0.01%
glutamine, 0.026% cysteine) (45) or 1% IsoVitaleX (Becton Dickinson, NJ)
and incubated at 34.5°C in 5% CO2. Preliminary FN binding experiments
(Fig. 1) and construction of mutants were conducted with bacteria grown on
chocolate agar (CA) plates supplemented with 5% FetalPlex (a fetal bovine
serum substitute; Gemini, CA) and 1 GGC. The following antibiotics were
used when appropriate: 1 g/ml chloramphenicol (Cm), 100 g/ml kanamycin
(Kan), and 100 g/ml streptomycin (Sm). Haemophilus influenzae strain
KW20 Rd clones expressing H. ducreyi genes from plasmid pLSKS were
routinely maintained on heme plates containing 50 g/l of hemin, 1%
IsoVitaleX, and 100 g/ml of Sm.
Construction of H. ducreyi mutants. (i) Construction of 35000HP ncaA
(FX521). To construct the single ncaA mutant FX521, PCR primers ncaA.01
(GAATTATTTTAAGCAATTTTTTTGC) and ncaA.05 (TTATTGAAAATTA
TATACAAAGCCTACACC) were used to amplify the ncaA locus, using crude
chromosomal DNA from 35000HP as a template and the following amplification
parameters: a single denaturation step of 1 min at 95°C and 30 amplification
cycles, each consisting of a 1-min denaturation at 95°C, annealing at 52°C for 1
min, and extension at 72°C for 2 min. The approximately 1-kb amplified product
was ligated into the pCR 2.1 TOPO vector (Invitrogen, Carlsbad, CA) to form
pUNCH1272. pUNCH1272 was digested with ClaI, made blunt-ended with T4
DNA polymerase, and ligated to a BglII- and Klenow-treated chloramphenicol
acetyltransferase (CAT) cassette from pNC40 (19) to form pUNCH1274.
pUNCH1274 was digested with SacI and EcoRV to obtain a 2.0-kb insert con-
taining the mutagenized ncaA locus. The latter insert was treated with Klenow
and ligated to NotI- and Klenow-treated mutagenesis plasmid pRSM1791 (14) to
form pUNCH1275. Finally, H. ducreyi strain 35000HP was electroporated with 1
g of pUNCH1275, with selection on CA containing 1 g/ml Cm (14). Cointe-
grate colonies were resolved by being streaked heavily onto CA containing 1
g/ml Cm and 40 g/ml X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyrano-
side), and white colonies were isolated and confirmed (see below).
(ii) Construction of 35000HP ompA2 (35000HP-SMS3). A promoterless
ompA2 open reading frame (ORF) was amplified by PCR, using DNA from H.
ducreyi strain 35000HP and the primers OmpA2-for-5 (5-TGGATTAGCGCG
TAACGATTATAGTG-3) and OmpA2-rev-5 (5-GCTCGTCCATCATCATT
TGCG-3). A -Km2 cassette (44) was blunt end ligated into a BssHII site
located 775 bp downstream of the start codon of the ompA2 ORF. The insert was
ligated into pRSM1791 and electroporated into 35000HP. Cointegrate colonies
were resolved as described above, and an ompA2 mutant, designated 35000HP-
SMS3, was recovered. Southern blot and PCR analyses confirmed that the
-Km2 cassette had been inserted into the ompA2 ORF (data not shown).
(iii) Construction of 35000HP dsrA ncaA (FX536). pUNCH1272 was digested
with ClaI, treated with Klenow, and ligated to an EcoRI- and Klenow-treated
Kan cassette from pUC4K (42, 43) to form pUNCH1297. The latter plasmid was
thereafter digested with SpeI and NotI, treated with Klenow, and ligated into
pRSM1791 to form pUNCH1298. To obtain FX536, strain 35000HP dsrA
(FX517) was electroporated with 1 g of pUNCH1298, and colonies were
screened as described above for strain 35000HP ncaA.
(iv) Construction of a dsrA mutant of H. ducreyi strain 35000HP with a Kan
cassette insertion (FX538). The strain 35000HP dsrA (FX517) contains the Cm
cassette inserted into the dsrA gene (20). However, the single mutant 35000HP
ftpA (35000HP-SMS1) already had this antibiotic marker inserted into the ftpA
(fine-tangle pilus) (5) gene. Thus, in order to construct a double mutant by using
strain 35000HP ftpA as a recipient, a single dsrA mutant with a different antibiotic
cassette insertion in the dsrA gene was constructed in H. ducreyi strain 35000HP.
To do so, pUNCH1260 (20), containing the complete dsrA ORF, was digested
with NdeI, Klenow treated, and ligated to an EcoRI- and Klenow-treated Kan
cassette from pUC4K to form pUNCH1299. The latter plasmid was thereafter
TABLE 1. Bacterial strains used in this study
Strain Description or genotype Source or reference
H. ducreyi strains
35000HP wt; human-passaged (HP) variant
of strain 35000HP
7, 23
FX504 35000HP hgbA::CAT 19
FX517 35000HP dsrA::CAT 20
FX521 35000HP ncaA::Kan This study
FX533 35000HP dltA::Kan 31
FX534 35000HP dsrA::CAT dltA::Kan 31
FX536 35000HP ncaA::Kan dsrA::CAT This study
FX538 35000HPdsrA::Kan This study
35000HP-SMS1 35000HP ftpA::mTn3 (Cm) 5
FX541 35000HP ftpA::mTn3 (Cm)
dsrA::CAT
This study
35000HP-SMS2 35000HP momp::Kan2 44
FX544 35000HP momp::Kan2 dsrA::CAT This study




HMC21 (V-1168) wt strain from Seattle, WA 18
FX528 HMC21 dsrA::CAT This study
HMC50 (010-2) wt strain from Jackson, MS 18
FX530 HMC50 dsrA::CAT 1
HMC54 (425) wt strain from Dominican Republic 18
FX529 HMC54 dsrA::CAT 1
H. influenzae strain
KW20 Rd Host for H. ducreyi clones American Type
Culture Collection
TABLE 2. Plasmids used in this study
Plasmid Description or relevant genotype and/orphenotype
Source or
reference
pCR2.1-TOPO PCR cloning vector; Kanr Ampr Invitrogen
pUC4K Source of Kanr cassette 42, 43
pNC40 Source of CAT cassette 19
pLSKS H. ducreyi shuttle vector; Smr 48
pRSM1791 Mutagenesis plasmid; -galactosidase
positive; Ampr
14
pUNCH1256 dsrA class I from 35000HP with CAT
cassette in pRSM1791
20
pUNCH1260 Complete dsrA class I gene from 35000HP
in pLSKS
20
pUNCH1272 ncaA PCR clone in pCR2.1-TOPO This study
pUNCH1274 ncaA with CAT cassette in PCR2.1-TOPO This study
pUNCH1275 ncaA with CAT cassette in pRSM1791 This study
pUNCH1286 Complete dltA class I gene from 35000HP
in pLSKS
31
pUNCH1296 Complete dsrA class II gene from CIP 542
in pLSKS
47
pUNCH1297 ncaA with Kan cassette in pCR2.1-TOPO This study
pUNCH1298 ncaA with Kan cassette in pRSM1791 This study
pUNCH1299 dsrA with Kan cassette insert in pLSKS This study
pUNCH1401 dsrA with Kan cassette insert in pRSM1791 This study
pUNCH1405 dsrA with Kan cassette insert in pRSM1791 This study
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digested with ApaI and XbaI, treated with Klenow, and ligated into NotI- and
Klenow-treated pRSM1791 to form pUNCH1401. To produce FX538, 1 g of
pUNCH1401 was electroporated into 35000HP. Mutants were obtained as de-
scribed above for strain 35000HP ncaA, except that cointegrate colonies were
plated on Kan-containing plates.
(v) Construction of 35000HP dsrA ftpA (FX541), 35000HP dsrA momp
(FX544), and 35000HP dsrA ompA (FX545). Mutant strain 35000HP dsrA ftpA
was obtained by PCR amplification of the mutated dsrA gene, using plasmid
pUNCH1405 (Kan insertion in the dsrA gene in pRSM1791) as the template and
the primers 301038-15 (5-TGGACAGCATTCCACTAACAGTC-3) and OPA
33 (5-CATCGTCGAACGCACACTG-3), using the following PCR conditions:
one denaturation cycle at 94°C for 5 min and 30 amplification cycles, each
consisting of a 1-min denaturation at 94°C, annealing at 50°C for 1 min, and
extension at 72°C for 4 min. The purified PCR product was subsequently elec-
troporated into the 35000HP ftpA mutant without prior cloning into the suicide
vector pRSM1791. Colonies were thereafter selected on Cm- and Kan-contain-
ing plates.
Mutant strains 35000HP dsrA momp and 35000HP dsrA ompA2 were obtained
using the same method as that for strain 35000HP dsrA ftpA, except that plasmid
pUNCH1256 (with the Cm antibiotic cassette in dsrA) was used as the template
for a PCR with primers 301038-15 and OPA 33. The product obtained from the
PCR was also directly electroporated into strains 35000HP momp (35000HP-
SMS2) and 35000HP ompA (35000HP-SMS3) to produce the double mutant
strains 35000HP dsrA momp and 35000HP dsrA ompA2, respectively.
(vi) Construction of HMC21 dsrA (FX528). The single dsrA mutant FX528 was
constructed in H. ducreyi strain HMC21 exactly as the dsrA mutant strains FX529
and FX530 were, as previously described (1).
Confirmation of the genotypes and phenotypes of the H. ducreyi mutants. The
hgbA (FX504) (6), dsrA (FX517) (13), dltA (FX533) (28), ftpA (35000HP-SMS1)
(5), and momp (35000HP-SMS2) (44) mutants have been characterized exten-
sively at the DNA and protein levels. As for the single ncaA (FX521) and dsrA
(FX538 [Km insert]) mutants and all of the double dsrA mutants, PCR products
obtained using whole-cell lysates as templates and specific primers were appro-
priately longer due to the presence of an antibiotic cassette inserted in the gene
of interest (data not shown). Furthermore, each mutant lacked expression of the
appropriate protein in a Western blot assay (Fig. 2, panels 2 to 4). However,
outer membrane profiles of 35000HP and the 35000HP ompA2 mutant were
similar (data not shown). We were unable to demonstrate a loss of OmpA2 in the
mutant via Western blotting due to the lack of a monoclonal antibody (MAb)
that specifically recognizes OmpA2 and the fact that the major outer membrane
protein (MOMP), which is expressed more abundantly than OmpA2, and
OmpA2 comigrate (30). The serum resistance phenotypes for all double dsrA
mutants were also evaluated and found to be similar to that of the single dsrA
mutant (FX517), except for that of 35000HP dsrA dltA, which has been shown to
be more serum susceptible than FX517 (31). All of the mutants used in this study
grew well on heme agar, the medium used for the FN and VN binding assays
described below.
Cloning of momp. The momp gene without its native promoter was PCR
amplified using whole cells of strain 35000HP as the template and primers
mompF (ATGGCTATCTAGAGGAGTATCAAAA) and mompR (GGGCTT
AATCTAGAGACTGAAAAT). XbaI sites (underlined in primers) were in-
cluded in the design of the primers. PCR was carried out under the following
conditions: one denaturation cycle at 95°C for 5 min and 30 amplification cycles,
each consisting of a 1-min denaturation at 95°C, annealing at 42°C for 1 min, and
extension at 72°C for 2 min, followed by 1 cycle at 72°C for 1 min. The PCR
products and the shuttle vector pLSKS (48) were treated with XbaI, and XbaI-
treated pLSKS was subsequently treated with shrimp alkaline phosphatase (New
England Biolabs, MA) to prevent religation. The restriction enzyme-treated
PCR products and plasmid were ligated at room temperature for 30 min, and 1
l of the ligation reaction mix was transformed into Escherichia coli DH5 and
FIG. 1. H. ducreyi binding to FN, but not to VN, is increased upon growth on heme agar. (A) Unlabeled FN binding assay. Suspensions of H.
ducreyi bacterial cells, grown on the indicated media, were mixed with purified FN (panels 1, 3, 4, and 5, first lane) or heat-inactivated normal
human serum (source of VN) (panel 2) for 30 min. After being washed to remove unbound ligands, bacterial cells were solubilized in Laemmli
sample buffer and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting to detect the bound ligands, as
indicated. The experiment presented is representative of at least three other similar experiments. Ponceau S staining (panel 5) of the nitrocellulose
membrane indicated approximately equal loading of total proteins for all strains. (B) FN standard curve. Lane 1, strain 35000HP incubated with
FN as described for panel A; lanes 2 to 6, FN standard curve using the indicated amounts of purified FN loaded directly into wells. (C) 125I-labeled
FN binding assay. Suspensions of H. ducreyi were mixed with purified 125I-labeled FN. After incubation and washing, bacterially associated cpm
were determined. Asterisks indicate statistically significant (P  0.01) differences in FN binding compared to that obtained for the wt strain H.
ducreyi 35000HP (DsrA) grown on heme (H). C, CA containing 5% FetalPlex; C	, CA without FetalPlex; H, gonococcal medium plates with
50 g/l hemin.
1610 LEDUC ET AL. INFECT. IMMUN.
electroporated into H. influenzae strain KW20 Rd and the H. ducreyi dsrA momp
mutant. Clones were selected on Sm-containing plates.
The momp gene with its native promoter was obtained the same way as the
momp gene without a promoter, except that primer mompF2 (TACCGGTTAA
TAGGCTCGAGTTT [XhoI site is underlined]) was used instead of mompF,
and an annealing temperature of 39°C was used in the PCR. Furthermore, PCR
products and plasmid pLSKS were treated with both XbaI and XhoI prior to
ligation.
FN and VN binding assays. Two methods were used to evaluate the role of
DsrA in FN binding by H. ducreyi, including an FN binding assay using unlabeled
FN and an FN binding assay using 125I-labeled FN. For the unlabeled FN binding
assay, suspensions containing bacterial growth from approximately 2  108
CFU/ml were prepared in GC broth (GCB) from 16- to 18-h heme agar plates.
One milliliter of each suspension was incubated with 500 ng of purified native FN
from human plasma, prepared in distilled water as described by the manufacturer
(catalog no. F2006; Sigma, MO), at 34.5°C in 5% CO2 for 30 min. The bacterial
cells were subsequently washed four times (for 1 h each) in GCB. Between the
third and fourth washes, the bacterial cells were transferred to a new microcen-
trifuge tube. After the fourth wash, the cells were resuspended in Laemmli
sample buffer. The bacterial cells were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis under reducing conditions and to Western
blotting using an anti-FN antibody (Sigma, MO) as previously described (31).
The viability of the bacterial cells after the 4-hour wash in GCB was determined
using plate counts. All isolates had 
50% viability after incubation for 4 h at
room temperature. Only three strains had CFU counts after incubation that were
statistically different from the CFU at the beginning of the incubation; they were
35000HP dsrA dlta FX534 (52%; P  0.0023), 35000HP dsrA momp FX544
(62%; P  0.014), and 35000HP dsrA ompA FX545 (60%; P  0.015). We used
NIH Image (version 1.63) to perform densitometry on the bands obtained in the
unlabeled FN binding assay. The numbers obtained with this program were used
to compare the density of the FN binding band for the parent strain to those for
the mutant strains. The density is expressed as the percentage of the density of
the FN binding band for the dsrA-positive strain in the experiment.
We determined the effect of preincubation of MAbs or purified proteins on the
ability of H. ducreyi to bind FN. Purified immunoglobulin G (IgG) MAbs or
purified proteins, each at 50 g/ml, were separately incubated for 30 min at
34.5°C with the bacterial suspensions prior to the addition of FN. The unlabeled
FN binding assay was subsequently used to determine FN binding by H. ducreyi.
The VN binding assay was performed the same way as the unlabeled FN
binding assay described above, except that 10% heat-inactivated normal human
serum was added to the bacterial suspensions as the source of VN. An anti-VN
antibody (Complement Technology, TX) was used for detection in the Western
blot.
The second assay used 125I-labeled FN to measure FN binding by H. ducreyi.
FN was iodinated by preactivation of two mCi of 125I-Na (Perkin-Elmer, MA) in
Iodo-Gen tubes (Pierce, IL) and then its addition to 200 g of purified plasma
FN (Sigma). The iodination reaction was allowed to proceed for 9 min on ice and
then quenched by the addition of 50 l of a solution of tyrosine (10 mg/ml). The
iodinated product was desalted on a Bio-Gel column (Bio-Rad, CA). The counts
per minute (cpm) associated with the iodinated purified FN (125I-FN) was de-
termined using a gamma counter, and the protein concentration was determined
using a bicinchoninic acid protein determination kit (Pierce, IL).
After iodination of FN, a dose-response curve was performed to determine the
quantity of 125I-FN to use for FN binding experiments. The quantity of 125I-FN
at half-saturation was determined to be approximately 15 ng. Based on this
information, 15 ng of 125I-FN was added to 200 l of a bacterial suspension
containing 0.5  108 CFU in a Multiscreen (Millipore, MA) plate and allowed to
incubate at 34.5°C for 45 min. After incubation, the wells were washed six times
with 200 l of phosphate-buffered saline and allowed to dry, and the bacterium-
associated cpm was determined using a gamma counter.
Production of MAb 1.82. MAb 1.82, raised against a recombinant DsrA class
I protein, was obtained from the same fusion that generated the anti-recombi-
nant DsrA MAb 4.79, which is described in detail in a previous publication (47).
MAb 1.82 binds a conformational epitope of H. ducreyi strain 35000HP but not
those of the dsrA mutant FX517. It also immunoprecipitates DsrA from H.
ducreyi whole cells (data not shown). The isotype for MAb 1.82 was determined
to be IgG2A by use of the SBA Clonotyping system (Southern Biotech, AL).
Statistical analysis. Statistical analyses were performed using the SigmaStat
program (Systat Software Inc., CA). The normal distribution of the data was first
determined using SigmaStat. Once this was established, a t test was used to assess
the differences between groups of data.
RESULTS
H. ducreyi binding to FN, but not VN, is increased upon
growth of H. ducreyi on heme agar. Two different methods
were used to detect FN binding by intact H. ducreyi. In the first
assay, hereafter termed the unlabeled FN binding assay, puri-
fied plasma FN bound by H. ducreyi was detected in Western
blots by use of an anti-FN antibody. In the second assay,
hereafter termed the 125I-labeled FN binding assay, purified
plasma FN was iodinated prior to incubation with intact H.
ducreyi, and gamma counting was used to assess FN bound by
H. ducreyi.
When cells were grown on CA, the standard growth me-
dium, H. ducreyi FN binding was marginal and inconsistent. It
was possible that the animal FNs in the FetalPlex present in
the CA medium inhibited subsequent human FN binding.
Therefore, we examined FN binding for H. ducreyi grown on
CA with or without the addition of FetalPlex, as well as that for
cells grown on heme plates. H. ducreyi grown on heme agar
bound FN at levels much greater than that of bacteria grown
on CA, regardless of the addition of FetalPlex (Fig. 1A, panel
1, first three lanes). In the 125I-labeled FN binding assay, strain
35000HP grown on heme agar bound 28 and 19 times more FN
(Fig. 1C, first three bars) than that grown on CA, with and
without FetalPlex, respectively (P  0.01 for CA with or with-
out FetalPlex compared to heme agar [Fig. 1C). We concluded
that the medium used for growth profoundly affected FN bind-
ing by H. ducreyi. Therefore, all subsequent FN binding assays
used bacteria grown on heme agar.
Since DsrA also mediates H. ducreyi binding to VN (16), the
effect of growth medium on VN binding was also investigated.
As opposed to FN binding, VN binding by H. ducreyi was not
affected by the growth medium. Bacteria grown on CA, with or
without the addition of FetalPlex, bound VN as well as those
grown on heme plates (Fig. 1A, panel 2).
DsrA is the major OMP mediating FN binding by H. ducreyi.
To determine the role of DsrA in FN binding by H. ducreyi, we
compared FN binding by the wild-type (wt) parent strain
35000HP and the dsrA isogenic null mutant FX517 (Fig. 1).
The parent strain bound approximately seven times more FN
than did the dsrA mutant strain (P  0.01) (Fig. 1C) in the
125I-labeled FN binding assay. Similar results were observed in
the unlabeled FN binding assay, where the dsrA mutant bound
very little purified FN compared to strain 35000HP (Fig. 1A,
panel 1, lanes 3 and 6).
We previously reported that the H. ducreyi lectin DltA
strongly binds to a number of N-linked glycoproteins, including
FN, in a ligand blot format (31). However, in that study, DltA
did not have a major role in FN binding by whole cells of H.
ducreyi. This conclusion is supported by the data presented in
Fig. 1A, where it is shown that even though the levels of
expression of DltA are identical between the parent and the
dsrA mutant strains (Fig. 1A, panel 4), the FN binding pheno-
types are different. Thus, binding of FN by H. ducreyi did not
correlate with expression of DltA.
The data presented above strongly suggest that DsrA is
involved in FN binding by H. ducreyi. However, the data also
show that there might be a second component involved in FN
binding, since there was residual FN binding by H. ducreyi dsrA
mutant strain FX517 in the absence of DsrA in both the un-
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labeled and 125I-labeled FN formats of the FN binding assay
(Fig. 1A, panel 1, and C). To determine if another compo-
nent(s) of the outer membrane of H. ducreyi was involved in
FN binding, double mutants that did not express dsrA and
other outer membrane protein (OMP) genes, such as dltA,
ncaA, ftpA, momp, and ompA2, were constructed. Single and
double mutants (Table 1) were then tested for FN binding.
All strains expressing dsrA bound FN comparably to parent
strain 35000HP in the unlabeled FN binding assay (Fig. 2).
Among strains not expressing dsrA (underlined dsrA in Fig. 2),
all dsrA double mutants, save strain 35000HP dsrA momp,
bound FN comparably to the single dsrA mutant in both assays.
Most importantly, FN binding by strain 35000HP dsrA momp
was not detected in the unlabeled FN binding assay (Fig. 2A,
panel 1) and was barely detectable in the 125I-labeled FN
binding assay (Fig. 2B), which correlated with the absence of
expression of momp. The values obtained in the 125I-labeled
FN binding assay for strains that had significantly different FN
binding from the wt were not statistically different from the
values obtained for the single dsrA mutant FX517 (P  0.402
for the dsrA dltA mutant, P  0.109 for the dsrA ncaA mutant,
P  0.948 for the dsrA ftpA mutant, P  0.115 for the dsrA
momp mutant, and P  0.238 for the dsrA ompA2 mutant).
H. ducreyi expresses two OmpA analogues, MOMP and
OmpA2 (30). MOMP is estimated to be five times more abun-
dant than OmpA2 in the outer membrane (44), and both
proteins migrate as a 37- to 39-kDa doublet and a heat-mod-
ifiable 43-kDa species (30, 40). MAb 2C7 binds to both MOMP
and OmpA2 (30, 40). The single momp mutant primarily
lacked expression of the 37- to 39-kDa doublet (Fig. 2A, panel
4), as described previously (30, 44). However, the ompA2 mu-
tant did not exhibit altered binding of 2C7 (Fig. 2A, panel 4)
due to the fact that it expresses MOMP.
To further define the role of MOMP in FN binding by H.
ducreyi, we cloned the momp gene under the control of the lac
promoter in the shuttle vector pLSKS and expressed it in E.
coli DH5, in H. influenzae strain KW20 Rd, and in the H.
ducreyi double dsrA momp mutant. We were unable to observe
expression of the momp gene in E. coli and H. influenzae, even
in the presence of IPTG (isopropyl--D-thiogalactopyrano-
side), and although the double dsrA momp mutant expressed
this construct, it did not do so to wt levels (data not shown).
Furthermore, the dsrA momp mutant complemented with the
momp construct did not bind more FN than the mutant com-
plemented with an empty vector (data not shown). In hopes of
increasing the expression level of momp, and therefore con-
firming a role for momp in FN binding by H. ducreyi, we
attempted to clone the momp gene into pLSKS with its native
promoter. However, we were unable to isolate a clone for any
of the three strains described above.
To confirm that the mutation in the dsrA gene was responsible
for the observed FN binding phenotype of the dsrA mutant
FX517, it was complemented in trans with plasmid pUNCH1260
(20), containing intact dsrA from strain 35000HP, and was assayed
for FN binding as described above. In the unlabeled FN binding
assay, expression of dsrA class I from pUNCH1260 (dsrAI) re-
stored FN binding by the dsrA mutant to levels comparable to that
seen for the wt parent strain 35000HP (Fig. 3A, panel 1). Con-
sistent with these results, the 125I-labeled FN binding assay
showed that FN binding by the dsrA mutant FX517 expressing
dsrAI in trans was significantly increased compared to that of the
dsrA mutant complemented with an empty vector (P  0.003).
Taken together, the data presented above suggest that DsrA is
the major OMP involved in FN binding by H. ducreyi and that
MOMP may have a minor role in this phenotype.
DsrA is sufficient to confer FN binding to the non-FN-bind-
ing H. influenzae strain KW20 Rd. Escherichia coli is typically
used as the host strain for expression of foreign genes and
analysis of resulting phenotypes. However, dsrA is unclonable
in E. coli due to its toxicity to this species (20). Thus, to study
the role of DsrA in the absence of other H. ducreyi factors, FN
binding was studied in H. influenzae strain KW20 Rd express-
ing dsrAI from plasmid pUNCH1260. H. influenzae strain
KW20 Rd does not appear to express a homolog of dsrA, since
only a homologous pseudogene of YadA with three frameshifts
was found in this strain (25, 26). In the unlabeled FN binding
FIG. 2. Expression of MOMP affects FN binding by H. ducreyi.
Both unlabeled (A) and 125I-labeled (B) FN binding assays were re-
peated, using a panel of mutants constructed in the 35000HP back-
ground (Table 1). Asterisks indicate strains with levels of FN binding
statistically different (P  0.05) from the level of FN binding by the wt
parent strain 35000HP. Strains not expressing dsrA are indicated with
underlining. The results presented in panel A are representative of at
least three other similar experiments. Ponceau S staining (panel 5) of
the nitrocellulose membrane indicated approximately equal loading of
total proteins for all the strains.
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assay, expression of dsrAI in H. influenzae KW20 Rd conferred
FN binding to this non-FN-binding strain (Fig. 3A, panel 1),
although the binding was not at the level seen for the H. ducreyi
dsrA mutant complemented with dsrAI. In the
125I-labeled FN
binding assay, FN binding was 10 times higher in strain H.
influenzae KW20 Rd expressing dsrAI (P  0.001) than in the
H. influenzae strain expressing an empty vector (Fig. 3B, dou-
ble asterisks). Expression of dsrAI in H. influenzae KW20 Rd
also conferred binding to VN to levels seen in the dsrA mutant
complemented with dsrAI (Fig. 3A, panel 2), while expression
of the dltA gene in H. influenzae did not confer FN or VN
binding (Fig. 3A, panels 1 and 2, and B), as expected. These
data confirm that DsrA is sufficient to confer FN binding to H.
influenzae in the absence of other H. ducreyi components.
DsrA class II confers FN and VN binding in both H. ducreyi
dsrA mutant FX517 and H. influenzae KW20 Rd. We and an-
other group (36, 47) were unable to mutagenize the dsrA and
LOS genes from H. ducreyi class II strains. Thus, to circumvent
this limitation, we studied the role of the dsrA class II gene
(dsrAII) in FN binding by expressing dsrAII from pUNCH1296
in both the null H. ducreyi dsrA mutant FX517 and the non-
FN-binding strain H. influenzae KW20 Rd. Expression of
dsrAII restored FN binding to wt levels in FX517
(P  0.008 versus vector alone) and conferred FN binding to
the non-FN-binding strain H. influenzae KW20 Rd (Fig. 3A,
panel 1, and B) (P  0.0002 versus H. influenzae KW20 Rd
vector alone). dsrAII also restored VN binding in the dsrA class
I mutant, as well as conferred VN binding to the non-VN-
binding H. influenzae strain KW20 Rd (Fig. 3A, panel 5).
These data suggest that DsrA proteins from both classes of H.
ducreyi strains mediate FN and VN binding.
Inhibition of H. ducreyi FN binding by antibodies. To deter-
mine the effect of antibodies on the binding between FN and
DsrA, MAbs to H. ducreyi OMPs were preincubated with H.
ducreyi cells prior to the addition of FN. FN was then added to
the bacterial suspension, and the unlabeled FN binding assay
was carried out as previously described (see Materials and
Methods). The anti-DsrA MAb 1.82 (this study) and the anti-
MOMP MAb 2C7 (11) were selected because they have been
shown to bind to the surface of H. ducreyi. Three other MAbs
(35), chosen as irrelevant control MAbs for this experiment,
were also used. These were MAbs 1.51, 4.23, and 6.18, which
are directed against HgbA. As shown in Fig. 4 (panel 1), MAb
1.82 partially blocked FN binding by H. ducreyi, while binding
was reduced to intermediate levels by MAb 2C7. None of the
other MAbs affected FN binding. VN binding by H. ducreyi
strain 35000HP was not affected by any MAb tested (Fig. 4,
panel 2).
Inhibition of H. ducreyi FN binding by selected proteins.
Earlier, we showed that FN binding by H. ducreyi grown on CA
was barely detectable and that FetalPlex could not account for
this inhibition (Fig. 1). Based on these data, we hypothesized
that hemoglobin (Hgb) present in the CA may inhibit FN
binding by H. ducreyi. To test this hypothesis, H. ducreyi strain
35000HP was preincubated with human or bovine Hgb or
human transferrin, a protein not present in CA medium, prior
to the addition of FN or human serum (a source of VN). While
Hgb from both sources greatly reduced FN binding by H.
ducreyi (Fig. 4, panel 1), neither affected the binding of VN by
H. ducreyi (Fig. 4, panel 2), consistent with the results shown in
Fig. 1. As expected, human transferrin did not affect FN or VN
binding by H. ducreyi.
Incubation of H. ducreyi with Hgb profoundly affected FN
binding by this microorganism (Fig. 4, panel 1). To determine
FIG. 3. Either class of DsrA is sufficient to confer FN binding to
the non-FN-binding strain H. influenzae KW20 Rd. The same FN
binding assays described in the legend to Fig. 1 (unlabeled [A] and
125I-labeled [B] FN binding assays) were used to test FN binding by the
H. ducreyi dsrA isogenic mutant FX517 (DsrA negative) and H. influ-
enzae KW20 Rd expressing either an empty vector (pLSKS), pLSKS
containing dsrA class I (dsrAI), pLSKS containing dltA, or pLSKS
containing dsrA class II (dsrAII). All strains were grown on heme
plates. Single asterisks represent statistically significant results (P 
0.01) compared to the H. ducreyi dsrA mutant expressing the empty
vector pLSKS, while double asterisks use H. influenzae KW20 Rd
expressing the empty vector pLSKS as the comparison strain (P 
0.01). The results presented in panel A are representative of at least
three other similar experiments. Ponceau S staining (not shown) of the
nitrocellulose membrane indicated approximately equal loading of to-
tal proteins for all the strains.
FIG. 4. FN binding by H. ducreyi is inhibited by an anti-DsrA MAb
and by hemoglobin. The effect of preincubation of MAbs or purified
protein on the ability of H. ducreyi to bind FN was measured using the
unlabeled FN binding assay (see Materials and Methods). A panel of
MAbs (purified IgGs), as well as hemoglobin (Hb) and transferrin
(Tf), each at 50 g/ml, were tested as potential inhibitors of FN and
VN binding by H. ducreyi. Ponceau S staining (not shown) of the
nitrocellulose membrane indicated approximately equal loading of to-
tal proteins for all the strains.
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if this could be due to steric hindrance, we evaluated FN
binding of the hgbA mutant (FX504) and the parent strain
35000HP upon growth on CA (with Hgb in the medium). We
reasoned that the hgbA mutant, which is unable to bind Hgb
(19), should be able to bind FN in the absence of Hgb bound
to the surface of the cell if Hgb prevents binding of FN by
steric hindrance. The hgbA mutant did not bind more FN than
the parent strain (data not shown) in the presence of Hgb,
suggesting that steric hindrance is not involved in preventing
FN binding by H. ducreyi in the presence of Hgb.
DsrA is the major OMP involved in FN binding by other
class I H. ducreyi strains. Although class II DsrA proteins are
almost identical at the amino acid level (47), class I DsrA
proteins are more variable (85% identity) (20). To determine
if the differences in amino acid sequence among the DsrA class
I proteins could affect FN and VN binding, previously con-
structed and characterized dsrA mutants FX529 and FX530 (1)
and a newly constructed dsrA mutant, FX528, as well as their
respective wt parent strains (HMC54, HMC50, and HMC21,
respectively), were assayed for FN and VN binding. Each dsrA
mutant bound less FN than its respective parent strain, al-
though the level of FN binding was heterogeneous among the
wt parent strains (Fig. 5, panel 1). VN binding phenotypes
were also as expected, with all wt parent strains tested binding
about equally to VN and their respective isogenic mutants
unable to bind VN (Fig. 5, panel 2). Thus, in all H. ducreyi
strains tested, DsrA was the major FN and VN binding protein.
DISCUSSION
DsrA is the major component involved in FN binding by H.
ducreyi. In this paper, we show four lines of evidence that DsrA
is the major factor required for binding by H. ducreyi to the
ECM protein FN. First, the single dsrA isogenic mutant strain
bound significantly less FN than the wt parent strain 35000HP
did. Moreover, the same phenotype was observed for three
other class I H. ducreyi strains and their isogenic dsrA mutants.
Second, expression of dsrA in trans in the single dsrA mutant
restored FN binding to levels comparable to that of the parent
strain, confirming that the reduced binding of FN by the dsrA
mutant strain FX517 was due to a mutation in dsrA and not
another locus. Third, an anti-DsrA MAb partially blocked FN
binding by H. ducreyi. Fourth, mutants containing mutations in
several outer membrane components bound levels of FN com-
parable to that of the parent strain, while most double mutants
with a mutation in dsrA bound FN at levels similar to that of
the single dsrA mutant.
MOMP may have a minor role in FN binding by H. ducreyi.
The data presented in this report demonstrate that DsrA is the
major FN binding factor in H. ducreyi. However, residual FN
binding by the dsrA mutant strain was also observed. This
residual FN binding might be attributed to MOMP, since a
double dsrA momp mutant bound less FN than the single dsrA
mutant FX517 in both FN binding assays, although the differ-
ence in levels of FN binding between the single dsrA and
double dsrA momp mutants did not reach statistical signifi-
cance in the 125I-labeled FN binding assay (P  0.115).
We attempted to demonstrate a role for MOMP in FN
binding by expressing the momp gene in three different hosts,
namely, E. coli DH5, H. influenzae strain KW20 Rd, and the
double dsrA momp H. ducreyi mutant (FX544). Although we
were able to express momp under the control of the lac pro-
moter in the dsrA momp mutant, it did not reach the levels
expressed by the wt strain, and FN binding by the dsrA momp
mutant complemented with this construct did not differ from
that of the dsrA momp mutant complemented with an empty
vector. Furthermore, we were unsuccessful in cloning the
momp gene under the control of its native promoter, suggest-
ing that this protein may be toxic when expressed at high levels,
even in its natural host.
The DsrA proteins from class I and class II H. ducreyi
strains are responsible for FN and VN binding. Similar to class
I DsrA, the DsrA proteins from class II strains were also able
to provide comparable FN and VN binding phenotypes to
those obtained with class I DsrA. A cloned class II dsrA gene
restored FN and VN binding in the isogenic dsrA mutant
FX517 to the same levels as those with class I DsrA and
conferred binding to the non-FN- and non-VN-binding H.
influenzae strain KW20 Rd.
The DsrA proteins from the two classes of H. ducreyi strains
share high identity in the C-terminal portion but very low
identity in the N-terminal two-thirds of the proteins. The dis-
similarity in these proteins raised the possibility that these
proteins may have different functions. However, the data pre-
sented here and previously (47) suggest that both classes of
DsrA have similar functions despite their divergent N termini,
since both classes of DsrA mediate serum resistance as well as
FN and VN binding. Either FN binding can be attributed to
the C-terminal part of the protein, which is 88% identical
among the DsrA proteins from the two classes, or features
other than the primary sequence in the divergent N-terminal
section of the proteins are responsible for this interaction. In
order to dissect the multifunctional roles of DsrA in H. ducreyi,
experiments are currently under way to construct DsrA pro-
FIG. 5. DsrA is the major OMP involved in FN binding by other wt
H. ducreyi class I strains. FN binding by three other wt H. ducreyi class
I strains and their respective dsrA isogenic mutants was determined
using the unlabeled FN binding assay described in the legend to Fig.
1A. Results are representative of similar experiments which were done
twice. Ponceau S staining (not shown) of the nitrocellulose membrane
indicated approximately equal loading of total proteins for all the
strains.
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teins that are involved only in adhesive properties and not
serum resistance and vice versa. Furthermore, the virulence of
these mutants will be examined in the experimental human
infection model of chancroid.
Expression of the two classes of DsrA protein in a non-FN-
binding H. influenzae strain conferred FN binding, although
not to the levels seen for H. ducreyi strain FX517 comple-
mented with dsrAI or dsrAII. The absence of another compo-
nent(s) may account for the lower levels of FN binding by H.
influenzae. This assumption is supported by the results pre-
sented in Fig. 3. Expression of dsrA genes from both classes of
H. ducreyi strains conferred VN binding by H. influenzae KW20
Rd to levels comparable to those seen in the dsrA mutant
complemented with either dsrA gene (Fig. 3, panel 2). How-
ever, this was not the case for FN binding, where expression of
either dsrA gene in H. influenzae KW20 Rd conferred 50% of
the FN binding level of the dsrA mutant complemented with
either class of dsrA gene. These data support the conclusion
that MOMP may have a role in FN binding by H. ducreyi.
A difference in FN binding was detected between the two
FN binding assays upon comparison of the H. influenzae strain
KW20 Rd and the H. ducreyi single dsrA mutant expressing the
dsrA gene (Fig. 3). FN binding measured by the 125I-labeled
FN binding assay was very similar between both H. ducreyi and
H. influenzae strains, while there was a substantial difference
between these strains in FN binding measured by the unla-
beled FN binding assay. We do not understand the reason(s)
for this observation. One possibility is that the affinity of FN for
dsrA expressed in H. influenzae is less than that for dsrA ex-
pressed in H. ducreyi. In this case, the FN bound at the surface
of the cell is more likely to be lost during the longer wash in the
unlabeled FN assay than it is in the 125I-labeled FN binding
assay. This “reduced” affinity for FN binding by H. influenzae
expressing dsrA may be due to additional H. ducreyi compo-
nents which are absent in H. influenzae and that contribute to
FN binding.
FN binding by H. ducreyi and virulence. Historically, limited
studies of ECM binding by H. ducreyi have been reported. In
the first in vitro ECM binding analysis, all 21 H. ducreyi strains
tested bound FN, and a protein was speculated to be involved
in this interaction (2). Later, Alfa and DeGagne showed that
the addition of purified FN inhibited the binding of H. ducreyi
to fibroblasts in a dose-dependent manner (4). A third in vitro
study of ECM binding by H. ducreyi confirmed previous studies
of FN binding by H. ducreyi, although no role for pili or full-
length LOS in FN binding by H. ducreyi could be demonstrated
(10). In the human experimental model of chancroid infection,
H. ducreyi associates with the ECM proteins fibrin and collagen
(9), and in natural chancroid, it is associated with fibrin only
(12).
The discrepancy between FN binding by H. ducreyi in vitro
and in vivo may be explained in several ways. H. ducreyi has not
been visualized in the skin of experimentally infected volun-
teers in the first 48 h postinoculation (9) and may interact with
FN early in the infection process, before organisms can be
visualized. Also, the MAb used for the in vivo FN binding
studies was developed against cellular FN (MAb 568; Novo-
castra Laboratories) (9), and it is not known whether this
antibody reacts with plasma FN. In the present study, only
plasma FN binding by H. ducreyi was examined, so we cannot
make any conclusion(s) about the interaction of H. ducreyi with
cellular FN.
We have shown that Hgb inhibits FN binding in vitro. Hgb is
present at sites of H. ducreyi infection and is an important
source of heme/iron for H. ducreyi in human experimental
infection (6). Chancroidal ulcers are vascular (33), and blood
at the site of infection is most likely a source of Hgb for H.
ducreyi. Since H. ducreyi can be visualized only after 48 h of
infection, it is possible that Hgb inhibits FN binding by H.
ducreyi in vivo, consistent with our in vitro findings. Clearly,
further studies are warranted to better understand how hemo-
globin and fibronectin interact with the H. ducreyi cell surface.
FN binding by other Oca proteins. The amino acid sequence
between amino acids 53 and 83 in YadA from Yersinia pseudo-
tuberculosis is responsible for FN binding, and this region is
absent in Yersinia enterocolitica YadA and H. ducreyi DsrA
(24). Furthermore, FN binding by Y. pseudotuberculosis
through the 53-83 region of YadA allows invasion through the
51 integrin receptor. However, there was residual binding in
53-83 YadA of Y. pseudotuberculosis, suggesting that another
section(s) of the protein may also bind FN. Experiments are
under way to determine the residues of DsrA which are re-
quired for plasma FN binding by H. ducreyi.
In conclusion, we have shown that the OMP DsrA is the
major mediator of human plasma FN binding by the gram-
negative bacterium H. ducreyi. Our results also suggest that
MOMP may play a minor role in the interaction of H. ducreyi
with FN.
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